Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

Chelsea C. Pinnix, Jatin J. Shah, Hubert Chuang, Colleen M. Costelloe, L. Jeffrey Medeiros, Christine F. Wogan, Valerie Reed, Grace L. Smith, Sarah Milgrom, Krina Patel, Jinhai Huo, Francesco Turturro, Jorge Romaguera, Luis Fayad, Yasuhiro Oki, Michelle A. Fanale, Jason Westin, Loretta Nastoupil, Fredrick B. Hagemeister, Alma RodriguezMuzaffar Qazilbash, Nina Shah, Qaiser Bashir, Sairah Ahmed, Yago Nieto, Chitra Hosing, Eric Rohren, Bouthaina Dabaja

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL. Materials and Methods We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed. Results The median age at diagnosis was 50.5 years. All patients had extranodal disease; 2 were positive for human immunodeficiency virus. Seven patients received hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)-based chemotherapy, 2 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and 1 received dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Radiotherapy (RT) was administered after a complete response to chemotherapy in 7 patients and a partial response in 1 patient. At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively. Conclusion PBL can be successfully treated with aggressive chemotherapy followed by RT. The treatment was well tolerated and can result in long-term survival for patients with limited-stage disease.

Original languageEnglish (US)
Pages (from-to)122-128
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume16
Issue number3
DOIs
StatePublished - Mar 1 2016

Keywords

  • Combined modality therapy
  • Early stage
  • Non-Hodgkin lymphoma
  • Radiotherapy
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review'. Together they form a unique fingerprint.

Cite this